While our current study focused on SON knockdown by siRNA or shRNA, the development of SON inhibitors and assessment of the therapeutic potential of targeting SON-mediated splicing in GBM will open the door to an innovative and unconventional method for treating GBM. This evidence concerns the gene SON and glioblastoma.